Payment overview · 2025
General Payments
$310.85
15 reported records · 7 companies
Healthcare provider profile · identity verified
Monte Ross Swanson, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PLAINVIEW, TX · NPI 1659665396
Verified facts
What the public records show
CMS Open Payments records show Monte Ross Swanson, M.D. received $310.85 in general payments during 2025 across 15 reported records.
Novo Nordisk Inc accounted for 33.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $104.88 | 33.7% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $68.69 | 22.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $52.71 | 17.0% | 3 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $40.72 | 13.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.29 | 4.9% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.79 | 4.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.77 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $310.85 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $104.88 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $85.25 | 4 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $40.72 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $34.25 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $27.19 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $25.24 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $14.79 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 67 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 118 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 38 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
67 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
118 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 493 | 94 |
| Atorvastatin Calcium | Atorvastatin Calcium | 490 | 152 |
| Levothyroxine Sodium | Levothyroxine Sodium | 395 | 107 |
| Tramadol Hcl | Tramadol Hcl | 355 | 121 |
| Gabapentin | Gabapentin | 325 | 100 |
| Lisinopril | Lisinopril | 289 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 238 | 79 |
| Metformin Hcl | Metformin Hcl | 237 | 68 |
| Losartan Potassium | Losartan Potassium | 219 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 200 | 68 |
| Meloxicam | Meloxicam | 167 | 66 |
| Potassium Chloride | Potassium Chloride | 165 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 162 | 52 |
| Furosemide | Furosemide | 150 | 51 |
| Trazodone Hcl | Trazodone Hcl | 146 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 141 | 38 |
| Omeprazole | Omeprazole | 141 | 47 |
| Escitalopram Oxalate | Escitalopram Oxalate | 140 | 50 |
| Azithromycin | Azithromycin | 138 | 109 |
| Tamsulosin Hcl | Tamsulosin Hcl | 135 | 50 |
| Tizanidine Hcl | Tizanidine Hcl | 126 | 43 |
| Mounjaro | Tirzepatide | 118 | 21 |
| Montelukast Sodium | Montelukast Sodium | 116 | 40 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 112 | 36 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 35 |
| Glimepiride | Glimepiride | 98 | 30 |
| Carvedilol | Carvedilol | 97 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 27 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 92 | 21 |
| Alendronate Sodium | Alendronate Sodium | 85 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 26 |
| Eliquis | Apixaban | 77 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 24 |
| Jardiance | Empagliflozin | 72 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 72 | 26 |
| Allopurinol | Allopurinol | 71 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 24 |
| Prednisone | Prednisone | 70 | 40 |
| Glipizide | Glipizide | 69 | 20 |
| Ondansetron Odt | Ondansetron | 68 | 33 |
| Farxiga | Dapagliflozin Propanediol | 67 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 67 | 21 |
| Simvastatin | Simvastatin | 66 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 23 |
| Cefdinir | Cefdinir | 63 | 49 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 11 |
| Bupropion Xl | Bupropion Hcl | 60 | 17 |
| Sertraline Hcl | Sertraline Hcl | 60 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 58 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 20 |
| Januvia | Sitagliptin Phosphate | 57 | 13 |
| Clonazepam | Clonazepam | 53 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 33 |
| Estradiol | Estradiol | 52 | suppressed |
| Pregabalin | Pregabalin | 52 | 14 |
| Buspirone Hcl | Buspirone Hcl | 50 | 12 |
| Amoxicillin | Amoxicillin | 48 | 43 |
| Fluconazole | Fluconazole | 44 | 29 |
| Alprazolam | Alprazolam | 43 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 11 |
| Finasteride | Finasteride | 42 | 13 |
| Nystatin | Nystatin | 39 | 29 |
| Glipizide Er | Glipizide | 38 | 12 |
| Ozempic | Semaglutide | 38 | 12 |
| Temazepam | Temazepam | 38 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | 13 |
| Celecoxib | Celecoxib | 36 | 15 |
| Naproxen | Naproxen | 35 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Lovastatin | Lovastatin | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Vraylar | Cariprazine Hcl | 34 | suppressed |
| Fentanyl | Fentanyl | 33 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | 12 |
| Lorazepam | Lorazepam | 33 | suppressed |
| Spironolactone | Spironolactone | 32 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 24 |
| Famotidine | Famotidine | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | 14 |
| Trulicity | Dulaglutide | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 23 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Glyburide | Glyburide | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 18 |
| Atenolol | Atenolol | 24 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Eszopiclone | Eszopiclone | 24 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 24 | 15 |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | 18 |
| Nabumetone | Nabumetone | 21 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 18 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 18 | 18 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 15 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Belsomra | Suvorexant | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Verapamil Er Pm | Verapamil Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $310.85 · 15 records | Novo Nordisk Inc | AIRSUPRA, BREZTRI, Cologuard Collection Kit, FARXIGA, INSPIRE, Kerendia, MOUNJARO, Ozempic, QULIPTA, Rybelsus, UBRELVY, VRAYLAR, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error